Angiogenesis-related gene products in preeclampsia
先兆子痫中血管生成相关的基因产物
基本信息
- 批准号:7365256
- 负责人:
- 金额:$ 20.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-02-01 至 2009-01-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAngiogenic FactorAngiogenic ProteinsAnimal ModelBindingBiological AssayBlood CirculationBlood Coagulation DisordersBlood VesselsCell Surface ReceptorsClinicalCytoplasmic TailDataDevelopmentDiseaseEdemaEquilibriumEtiologyEventFunctional disorderGene ExpressionGene Expression RegulationHeterozygoteHypertensionHypoxiaImmunohistochemistryIn VitroIschemiaKidney FailureKnockout MiceLeadLesionMessenger RNAModelingMolecularMorbidity - disease ratePathogenesisPatient currently pregnantPatientsPlacentaPlacental Growth FactorPlacentationPlayPre-EclampsiaPregnancyPregnant WomenPreventionProductionProperdinProteinsProteinuriaRNA SplicingRattusReceptor Protein-Tyrosine KinasesReportingResearch PersonnelRodentRoleSerumSymptomsTestingTherapeuticTimeTranscriptional ActivationUp-RegulationVariantVascular Endothelial Growth Factor ReceptorVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth FactorsWeekWomanangiogenesisantiangiogenesis therapycytotrophoblastfallsfetalglomerular filtrationin vivoin vivo Bioassayinsightmortalitynormotensivenovelnovel therapeuticspodocytepreventprogramsresearch studyresponse
项目摘要
DESCRIPTION (provided by applicant): Preeclampsia (PE) is a disease, which affects 5-7% of all pregnancies and is characterized by severe hypertension, proteinuria and edema. Endothelial dysfunction plays an important role in the pathogenesis of this disorder; however, the etiology and mechanisms are still unknown. We recently found that placentas from preeclamptic patients produce an excess of a naturally occurring anti-angiogenic protein, sFIt-1 (soluble fms-like tyrosine kinase-1), resulting in increased serum levels in patients with PE as compared to normotensive pregnant women. Fit-1 is one of the tyrosine kinase receptors for vascular endothelial growth factor (VEGF) and placental growth factor (PIGF). sFIt-1, a secreted splice variant of Fit-1 (lacking the transmembrane and cytoplasmic domains) potently antagonizes VEGF and PIGF, by preventing their binding to the cell-surface receptor. Moreover, we have found that the ratio of anti-angiogenic (sFIt-1) to pro-angiogenic (VEGF + PIGF) proteins in the maternal bloodstream at the time of delivery is substantially elevated in preeclamptic women as compared with control pregnant women. In vitro, preeclamptic serum but not normal pregnant serum induces endothelial dysfunction due to excess sFIt-1, which can be rescued by exogenous VEGF and PIGF. Finally, we have preliminary data that administration of exogenous sFIt-1 to pregnant rats induces hypertension, heavy proteinuria and glomerular endotheliosis, the classic lesion of PE. We therefore hypothesize that alteration in the angiogenic balance due to excess sFLt-1 results in the development of PE. This proposal aims to clarify the role of sFIt-1 and altered angiogenic balance in the pathogenesis of PE. We will first characterize our sFIt-1 induced animal model for PE and will test several therapeutic compounds in an attempt to find new treatment options for patients with PE. We will then elucidate the mechanisms of systemic vascular dysfunction and placental cytotrophoblast dysfunction induced by excess sFIt-1 and altered angiogenic balance using both in vitro and in vivo experiments. Finally, we will focus on studying the transcriptional and post-transcriptional regulatory mechanisms of sFIt-1 production by placental cytotrophoblasts. These focused studies will form the beginnings of a framework for understanding the role of angiogenesis-related gene products in pathogenesis of PE and for exploring novel avenues for the treatment of PE.
描述(由申请人提供):先兆子痫(PE)是一种疾病,影响所有妊娠的5-7%,其特征是严重的高血压、蛋白尿和水肿。内皮功能障碍在该病的发病机制中起重要作用,但其病因和机制尚不清楚。我们最近发现先兆子痫患者的胎盘产生过量的天然抗血管生成蛋白sFIt-1(可溶性fms样酪氨酸激酶-1),导致PE患者的血清水平高于血压正常的孕妇。Fit-1是血管内皮生长因子(VEGF)和胎盘生长因子(PlGF)的酪氨酸激酶受体之一。sFIt-1是Fit-1的分泌剪接变体(缺乏跨膜和胞质结构域),通过阻止VEGF和PlGF与细胞表面受体结合而有效拮抗VEGF和PlGF。此外,我们发现,与对照孕妇相比,先兆子痫孕妇分娩时母体血流中抗血管生成蛋白(sFIt-1)与促血管生成蛋白(VEGF + PlGF)的比例大幅升高。在体外,先兆子痫血清而不是正常妊娠血清诱导内皮功能障碍,由于过量的sFIt-1,这可以通过外源性VEGF和PIGF拯救。最后,我们有初步的数据表明,外源性sFIT-1给药妊娠大鼠诱导高血压,重蛋白尿和肾小球内皮增生,PE的经典病变。因此,我们推测,由于过量sFLt-1导致的血管生成平衡的改变导致PE的发展。该提案旨在阐明sFIt-1和血管生成平衡改变在PE发病机制中的作用。我们将首先表征sFIt-1诱导的PE动物模型,并将测试几种治疗化合物,试图为PE患者找到新的治疗选择。然后,我们将阐明全身血管功能障碍和胎盘细胞滋养层功能障碍诱导过量的sFIT-1和改变血管生成的平衡,在体外和体内实验的机制。最后,我们将重点研究胎盘细胞滋养层细胞产生sFIt-1的转录和转录后调节机制。这些重点研究将形成一个框架的开始,了解血管生成相关的基因产物在PE发病机制中的作用,并探索治疗PE的新途径。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
S. Ananth Karumanchi其他文献
ニコチンアミドは妊娠高血圧に有効である
烟酰胺对妊娠高血压有效
- DOI:
- 发表时间:
2012 - 期刊:
- 影响因子:0
- 作者:
高橋信行;Feng Li;Charles Jennette;S. Ananth Karumanchi;Oliver Smithies;高橋信行;高橋信行 - 通讯作者:
高橋信行
993 Plasma sFlt-1/PlGF ratio in mom and severe adverse neonatal outcomes in non-preeclamptic patients
- DOI:
10.1016/j.ajog.2023.11.1020 - 发表时间:
2024-01-01 - 期刊:
- 影响因子:
- 作者:
Jimmy Espinoza;Vinicius Calsavara;Elizabeth Lemoine;Sarah Kilpatrick;Ravi Thadhani;S. Ananth Karumanchi - 通讯作者:
S. Ananth Karumanchi
ニコチンアミドは妊娠高血圧腎症に有効である
烟酰胺对先兆子痫有效
- DOI:
- 发表时间:
2012 - 期刊:
- 影响因子:0
- 作者:
高橋信行;Feng Li;Charles Jennette;Oliver Smithies;S. Ananth Karumanchi - 通讯作者:
S. Ananth Karumanchi
1059 Maternal Angiogenic Imbalance & Placental Sexual Dimorphism
- DOI:
10.1016/j.ajog.2023.11.1086 - 发表时间:
2024-01-01 - 期刊:
- 影响因子:
- 作者:
Elizabeth Lemoine;Vinicius Calsavara;Ravi Thadhani;Sarah Kilpatrick;S. Ananth Karumanchi;Kim Boggess - 通讯作者:
Kim Boggess
Lipid-delivery system could treat life-threatening pregnancy complication
脂质递送系统可治疗危及生命的妊娠并发症
- DOI:
10.1038/d41586-024-03853-w - 发表时间:
2024-12-11 - 期刊:
- 影响因子:48.500
- 作者:
Ravi Thadhani;S. Ananth Karumanchi - 通讯作者:
S. Ananth Karumanchi
S. Ananth Karumanchi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('S. Ananth Karumanchi', 18)}}的其他基金
Placental Organoids for Modeling and Treating Preeclampsia
用于建模和治疗先兆子痫的胎盘类器官
- 批准号:
10464766 - 财政年份:2022
- 资助金额:
$ 20.54万 - 项目类别:
Role of ADAMTS13 in Maternal Complications of Preeclampsia
ADAMTS13 在先兆子痫孕产妇并发症中的作用
- 批准号:
9119325 - 财政年份:2016
- 资助金额:
$ 20.54万 - 项目类别:
2012 Endothelial Cell Phenotypes in Health & Disease GRC/GRS
2012 健康中的内皮细胞表型
- 批准号:
8390350 - 财政年份:2012
- 资助金额:
$ 20.54万 - 项目类别:
Redefining Vitamin D Deficiency: The Role of Bioavailable Vitamin D
重新定义维生素 D 缺乏症:生物可利用维生素 D 的作用
- 批准号:
9015435 - 财政年份:2012
- 资助金额:
$ 20.54万 - 项目类别:
Angiogenesis-related gene products in preeclampsia
先兆子痫中血管生成相关的基因产物
- 批准号:
7010387 - 财政年份:2005
- 资助金额:
$ 20.54万 - 项目类别:
Angiogenesis-related gene products in preeclampsia
先兆子痫中血管生成相关的基因产物
- 批准号:
7174642 - 财政年份:2005
- 资助金额:
$ 20.54万 - 项目类别:
Angiogenesis-related gene products in preeclampsia
先兆子痫中血管生成相关的基因产物
- 批准号:
6870361 - 财政年份:2005
- 资助金额:
$ 20.54万 - 项目类别:
Role of VEGF in Glomerular Endothelial Health & Diseases
VEGF 在肾小球内皮健康中的作用
- 批准号:
7239601 - 财政年份:2004
- 资助金额:
$ 20.54万 - 项目类别:
Role of VEGF in Glomerular Endothelial Health & Diseases
VEGF 在肾小球内皮健康中的作用
- 批准号:
6822487 - 财政年份:2004
- 资助金额:
$ 20.54万 - 项目类别:
相似海外基金
How angiogenic factor induces immunosuppressive cells to tumor microenvironment
血管生成因子如何诱导免疫抑制细胞进入肿瘤微环境
- 批准号:
22KJ0818 - 财政年份:2023
- 资助金额:
$ 20.54万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10711027 - 财政年份:2021
- 资助金额:
$ 20.54万 - 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10297199 - 财政年份:2021
- 资助金额:
$ 20.54万 - 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10625314 - 财政年份:2021
- 资助金额:
$ 20.54万 - 项目类别:
Validation of Adenylosuccinate as a Novel Endogenous Pro-Angiogenic Factor in the Brain
腺苷琥珀酸作为大脑中新型内源性促血管生成因子的验证
- 批准号:
10405070 - 财政年份:2021
- 资助金额:
$ 20.54万 - 项目类别:
Physiological role of anti-angiogenic factor thrombospondin in the regulation of endometrial function during early pregnancy in cattle
抗血管生成因子血小板反应蛋白在牛妊娠早期子宫内膜功能调节中的生理作用
- 批准号:
20K06385 - 财政年份:2020
- 资助金额:
$ 20.54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of lymphangiogenic regulatory mechanism of angiogenic factor CCN2 through tumor-associated macrophage
阐明血管生成因子CCN2通过肿瘤相关巨噬细胞的淋巴管生成调节机制
- 批准号:
17K11866 - 财政年份:2017
- 资助金额:
$ 20.54万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of vascular stabilization mechanism by anti-angiogenic factor vasohibin-1
抗血管生成因子 vasohibin-1 阐明血管稳定机制
- 批准号:
15K20874 - 财政年份:2015
- 资助金额:
$ 20.54万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
angiogenic therapy for cerebral infarction with anti^sense homology derived peptide targeting angiogenic factor
靶向血管生成因子的反义同源肽治疗脑梗死
- 批准号:
15K15523 - 财政年份:2015
- 资助金额:
$ 20.54万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
The development of the anti-angiogenic factor VEGF-A165b quantification methods for cardiovascular disease.
心血管疾病抗血管生成因子 VEGF-A165b 定量方法的开发。
- 批准号:
26860367 - 财政年份:2014
- 资助金额:
$ 20.54万 - 项目类别:
Grant-in-Aid for Young Scientists (B)